The era of cheap, widely available compounded GLP-1 medications is ending. The FDA has declared semaglutide and tirzepatide shortages resolved, enforcement discretion periods have expired, courts have upheld the agency's position, and a proposed rule would permanently bar bulk compounding of these drugs. Here's what this means for your wallet.
What Happened: The Regulatory Timeline
Compounded GLP-1s existed in a regulatory gray zone that depended on FDA shortage declarations. When semaglutide and tirzepatide were on the shortage list, compounding pharmacies could legally produce them under Sections 503A and 503B of the FD&C Act. Here's how that window closed:
| Date | Event | Impact |
|---|---|---|
| 2022-2024 | FDA shortage declarations | Compounding legally permitted |
| Feb 2025 | Semaglutide shortage resolved | 503A window starts closing |
| Apr 22, 2025 | 503A enforcement discretion ends | State pharmacies can't compound copies |
| May 22, 2025 | 503B enforcement discretion ends | Outsourcing facilities restricted |
| Feb 2026 | FDA announces intent to act against non-approved GLP-1s | Market-wide concern |
| May 2026 | Proposed 503B Bulks List exclusion | Would permanently bar bulk compounding |
| July 2026 | FDA Advisory Committee on peptides | Broader regulatory review |
How This Affects Pricing
Short-term: prices are holding
Despite the regulatory pressure, most compounding providers continue operating and haven't raised prices. GobyMeds still offers semaglutide at $99/month, Oak Longevity at $130, and mid-tier providers at $149-249. The market is competitive enough that providers are absorbing regulatory compliance costs rather than passing them to patients.
Medium-term: expect consolidation
Smaller compounding pharmacies without the resources to navigate FDA enforcement will exit the market. This consolidation will reduce competition and could push prices upward. Expect the $99-130 tier to face the most pressure — these low-margin providers have the least runway to absorb compliance costs.
Long-term: brand-name prices are falling to meet compounded
This is the key insight most coverage misses. While compounded prices may rise slightly, brand-name prices are falling dramatically. Wegovy oral at $149/month, Foundayo at $149/month, and Novo Nordisk's announced 50% list price cut to $675/month in 2027 all narrow the gap. The pricing endgame may be brand-name and compounded converging around $150-300/month.
What This Means for Your Treatment
If you're currently on compounded GLP-1s
Your medication supply is not immediately at risk. Providers using licensed compounding pharmacies are still operating. But having a transition plan is smart: know your brand-name options (Wegovy oral, Foundayo) and their pricing. If your provider suddenly stops offering compounded semaglutide, you'll want to switch without a treatment gap.
If you're considering starting treatment
The compounded-vs-brand calculation now includes regulatory risk as a factor. Starting with a brand-name oral option ($149/month) eliminates that risk. Starting with compounded ($99-179/month) saves money but carries supply uncertainty. Either choice is reasonable depending on your risk tolerance and budget.
The Safety Dimension
The FDA's crackdown isn't purely bureaucratic. The agency cited 455+ adverse events for compounded semaglutide and 320+ for compounded tirzepatide. Many involved dosing errors from patients self-administering from multi-dose vials — a problem that doesn't exist with prefilled brand-name pens. Counterfeit compounded products labeled with fake pharmacy names have also been identified.
This doesn't mean all compounded GLP-1s are unsafe. Providers on our board that use LegitScript-certified operations and licensed 503A/503B pharmacies have demonstrated quality records. But the variance in quality across the broader market is real, and it's part of what the FDA is trying to address.